A5010660745- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Esophageal and GI Pathology
- Gastrointestinal disorders and treatments
- Gastrointestinal Bleeding Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Metabolism, Diabetes, and Cancer
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Biliary and Gastrointestinal Fistulas
- Poverty, Education, and Child Welfare
- Congenital Diaphragmatic Hernia Studies
- BRCA gene mutations in cancer
- Gender, Labor, and Family Dynamics
- Orthopedic Infections and Treatments
- Bone Tumor Diagnosis and Treatments
- Pancreatitis Pathology and Treatment
- Oral Health Pathology and Treatment
- Cancer Cells and Metastasis
- Adolescent Sexual and Reproductive Health
- Lymphatic System and Diseases
- Oral and Maxillofacial Pathology
- Genital Health and Disease
Centro Oncológico de Galicia
2019-2024
Hospital Universitario HM Sanchinarro
2024
Vall d'Hebron Hospital Universitari
2019-2023
University of Talca
2020-2022
HM Hospitales
2021
Hospital Vargas
2007-2009
University of Chile
1998
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor metastasis pairs: 252 targeted gene sequencing, 152 RNA 67 single nucleotide polymorphism arrays), we found a driver role for GATA1 MEN1 somatic mutations. Metastases were enriched ESR1, PTEN, CDH1, PIK3CA, RB1 mutations; MDM4 MYC amplifications; ARID1A deletions. An increase clonality was...
Abstract Purpose: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). Patients Methods: The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet comprised intravenous atezolizumab...
Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/
Introducción: La educación sexual es esencial en la formación integral, ayuda a comprender los cambios biológicos, valorar el propio cuerpo y de demás. Sin embargo, factores como falta políticas escolares, escasa comunicación familiar desinformación incrementan vulnerabilidad jóvenes problemas embarazos no planificados enfermedades transmisión sexual. Metodología: El estudio utiliza un enfoque cualitativo teoría fundamentada para analizar integración emancipadora currículo del Bachillerato...
Background: To immunohistochemically evaluate the association between presence of cancer-associated fibroblasts (CAFs) and tumour expression podoplanin (PDPN) in head neck squamous cell carcinoma (HNSCC) their with clinicopathological variables.Material Methods: A tissue microarray (TMA) biopsy sections from patients diagnosed HNSCC was stained antibodies against CAFs marker, α-smooth muscle actin (α-SMA), PDPN.We subsequently evaluated to determine them variables including age, primary...
Background: The 21-gene Oncotype DX Breast Recurrence Score® assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, HER2− early breast cancer (EBC). KARMA Dx study evaluated the impact results (RS) on treatment decision EBC high-risk clinicopathological characteristics whom (CT) was considered. Methods: Eligible were candidates if CT considered standard recommendation by local guidelines. Three cohorts predefined: (A) pT1-2, pN0/N1mi, grade...
<div>AbstractPurpose:<p>To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC).</p>Patients Methods:<p>The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet...
<div>AbstractPurpose:<p>To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC).</p>Patients Methods:<p>The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet...
Background: Patients (pts) with ER+, HER2– early breast cancer (EBC) do not universally benefit from adding adjuvant chemotherapy (CT) to hormonal treatment (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay is uniquely designed and validated guide CT decisions in this population. Methods: primary objective of the KARMA Dx study was assess impact RS result on recommendations high-risk patients for whom uncertain. Secondary evaluation physicians' confidence their...
Abstract Background: Different approaches for treatment de-escalation are being investigated; however, the current ongoing phase III adjuvant trials with CDK4/6 inhibitors not addressing question if these drugs can replace multi-agent chemotherapy in high-risk early breast cancer. Here, we present primary results of CORALLEEN 2 trial, which evaluates efficacy ribociclib plus endocrine therapy (ET) as neoadjuvant patients Luminal B disease. Methods: is a parallel, multicenter, two-arm,...
Introducción: El fibroma osificante (FO) y el cemento (FCO) son patologÃas distintas, que hasta 2017 se consideraban como una. A la fecha no han comparado las caracterÃsticas del FO FCO. La presente revisión tuvo objetivo analizar clÃnicas, epidemiológicas e imagenológicas FCO en los casos publicados.